新型广谱抗微小核糖核酸病毒药物WIN 51711的体外活性
In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.
作者信息
Otto M J, Fox M P, Fancher M J, Kuhrt M F, Diana G D, McKinlay M A
出版信息
Antimicrob Agents Chemother. 1985 Jun;27(6):883-6. doi: 10.1128/AAC.27.6.883.
Abstract
WIN 51711 (5-[7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3-methylisoxazole), a new antipicornavirus drug, is a potent inhibitor of human entero- and rhinoviruses at concentrations not inhibitory to HeLa cell growth. In plaque reduction assays, WIN 51711 reduced plaque formation by 9 enteroviruses and 33 rhinoviruses, with MICs of 0.004 to 0.17 and 0.004 to 6.2 micrograms/ml, respectively. Addition of WIN 51711 to infected cells at concentrations of 0.02 to 5.0 micrograms/ml reduced the yield of picornaviruses by 90%. Other RNA viruses (nonpicornaviruses) and DNA viruses were unaffected by the compound.
摘要
WIN 51711（5-[7-[4-(4,5-二氢-2-恶唑基)苯氧基]庚基]-3-甲基异恶唑）是一种新型抗微小核糖核酸病毒药物，在不抑制HeLa细胞生长的浓度下，它是人类肠道病毒和鼻病毒的强效抑制剂。在蚀斑减少试验中，WIN 51711使9种肠道病毒和33种鼻病毒的蚀斑形成减少，其最小抑菌浓度分别为0.004至0.17微克/毫升和0.004至6.2微克/毫升。以0.02至5.0微克/毫升的浓度将WIN 51711添加到受感染细胞中，可使微小核糖核酸病毒的产量降低90%。其他RNA病毒（非微小核糖核酸病毒）和DNA病毒不受该化合物影响。
相似文献
1
In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.新型广谱抗微小核糖核酸病毒药物WIN 51711的体外活性
Antimicrob Agents Chemother. 1985 Jun;27(6):883-6. doi: 10.1128/AAC.27.6.883.
2
In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.新型广谱抗微小核糖核酸病毒药物WIN 54954的体外和体内活性
Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74. doi: 10.1128/AAC.33.12.2069.
3
WIN 51711, a new systematically active broad-spectrum antipicornavirus agent.
J Antimicrob Chemother. 1985 Sep;16(3):284-6. doi: 10.1093/jac/16.3.284.
4
Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.新型抗病毒药物WIN 51711对鼻病毒和脊髓灰质炎病毒脱壳的预防作用
Antimicrob Agents Chemother. 1986 Jul;30(1):110-6. doi: 10.1128/AAC.30.1.110.
5
Isoxazoles with antipicornavirus activity.
J Med Chem. 1985 Jun;28(6):748-52. doi: 10.1021/jm00383a010.
6
Chiral discrimination and antipicornavirus activity of 6-oxazolinylisoflavan.
Chirality. 1993;5(5):356-8. doi: 10.1002/chir.530050515.
7
Inhibition of poliovirus uncoating by disoxaril (WIN 51711).双异丙氧乙酰胺（WIN 51711）对脊髓灰质炎病毒脱壳的抑制作用。
Virology. 1987 Sep;160(1):281-5. doi: 10.1016/0042-6822(87)90075-4.
8
[[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating.[[(4,5-二氢-2-恶唑基)苯氧基]烷基]异恶唑。微小核糖核酸病毒脱壳抑制剂。
J Med Chem. 1985 Dec;28(12):1906-10. doi: 10.1021/jm00150a025.
9
In vitro and in vivo antipicornavirus activity of some phenoxypyridinecarbonitriles.某些苯氧基吡啶腈的体外和体内抗小RNA病毒活性
Antimicrob Agents Chemother. 1985 Dec;28(6):745-50. doi: 10.1128/AAC.28.6.745.
10
Antipicornavirus activity of tetrazole analogues related to disoxaril.与双异丙酚相关的四唑类似物的抗微小核糖核酸病毒活性
J Med Chem. 1993 Oct 29;36(22):3240-50. doi: 10.1021/jm00074a004.
引用本文的文献
1
Structure of Human Enterovirus 70 and Its Inhibition by Capsid-Binding Compounds.人肠道病毒 70 结构及其衣壳结合化合物的抑制作用。
J Virol. 2022 Sep 14;96(17):e0060422. doi: 10.1128/jvi.00604-22. Epub 2022 Aug 8.
2
Targeting the Virus Capsid as a Tool to Fight RNA Viruses.靶向病毒衣壳作为抗击 RNA 病毒的工具。
Viruses. 2022 Jan 18;14(2):174. doi: 10.3390/v14020174.
3
Antivirals blocking entry of enteroviruses and therapeutic potential.抗病毒药物阻断肠道病毒进入及其治疗潜力。
J Biomed Sci. 2021 Jan 15;28(1):10. doi: 10.1186/s12929-021-00708-8.
4
Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.回到未来：广谱肠道病毒衣壳结合抑制剂的研发进展。
Eur J Med Chem. 2019 Sep 15;178:606-622. doi: 10.1016/j.ejmech.2019.06.008. Epub 2019 Jun 11.
5
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host.震动、摇晃与滚动：黄病毒颗粒动力学对其与宿主相互作用的影响
Virology. 2015 May;479-480:508-17. doi: 10.1016/j.virol.2015.03.025. Epub 2015 Mar 30.
6
Endocytosis of integrin-binding human picornaviruses.整合素结合型人微小核糖核酸病毒的内吞作用。
Adv Virol. 2012;2012:547530. doi: 10.1155/2012/547530. Epub 2012 Nov 27.
7
Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity.鼻病毒衣壳动力学的长程相关性有助于脱壳和抗病毒活性。
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5271-6. doi: 10.1073/pnas.1119174109. Epub 2012 Mar 21.
8
The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.人类鼻病毒：对人类的病理影响、抗鼻病毒药物的作用机制及研发策略。
Med Res Rev. 2011 Jan;31(1):42-92. doi: 10.1002/med.20176.
9
Understanding the mechanisms of viral induced asthma: new therapeutic directions.了解病毒诱发哮喘的机制：新的治疗方向。
Pharmacol Ther. 2008 Mar;117(3):313-53. doi: 10.1016/j.pharmthera.2007.11.002. Epub 2008 Jan 29.
10
Rhinovirus chemotherapy.鼻病毒化疗
Antiviral Res. 2006 Sep;71(2-3):391-6. doi: 10.1016/j.antiviral.2006.03.011. Epub 2006 Apr 18.
本文引用的文献
1
Antiviral activity of arildone on deoxyribonucleic acid and ribonucleic acid viruses.阿立多对脱氧核糖核酸病毒和核糖核酸病毒的抗病毒活性。
Antimicrob Agents Chemother. 1980 Aug;18(2):276-80. doi: 10.1128/AAC.18.2.276.
2
Prevention of human poliovirus-induced paralysis and death in mice by the novel antiviral agent arildone.新型抗病毒药物阿立多能预防小鼠因人类脊髓灰质炎病毒导致的麻痹和死亡。
Antimicrob Agents Chemother. 1982 Dec;22(6):1022-5. doi: 10.1128/AAC.22.6.1022.
3
Portraits of viruses: the picornaviruses.病毒的画像：微小核糖核酸病毒
Intervirology. 1983;20(2-3):61-100. doi: 10.1159/000149376.
4
Enteroviruses and meningitis.肠道病毒与脑膜炎
Pediatr Infect Dis. 1983 Jul-Aug;2(4):333-41. doi: 10.1097/00006454-198307000-00019.
5
Plaque assay of Herpesvirus hominis on human embryonic fibroblasts.人疱疹病毒在人胚成纤维细胞上的蚀斑测定
Proc Soc Exp Biol Med. 1969 Jun;131(2):588-92. doi: 10.3181/00379727-131-33932.
6
Preliminary studies of the mode of action of arildone, a novel antiviral agent.新型抗病毒药物阿立多的作用模式的初步研究。
Antimicrob Agents Chemother. 1979 Jun;15(6):813-9. doi: 10.1128/AAC.15.6.813.
7
Inhibition of uncoating of poliovirus by arildone, a new antiviral drug.
Virology. 1979 Sep;97(2):307-15. doi: 10.1016/0042-6822(79)90342-8.
Zotero 插件